Last reviewed · How we verify

NCT04517955

TAVI in Intermediate Risk Septuagenarians With Risk Factors Not Captured by the Traditional Surgical Risk Scores

Status unknown Last updated 19 August 2020
What this trial tests

trial testing Transcatheter Aortic Valve Implantation (TAVI) in Transcatheter Aortic Valve Replacement in 80 participants. Status unknown.

Timeline
1 July 2020
Primary endpoint
1 September 2022
30 March 2025

Quick facts

Lead sponsorUniversity of Athens
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment80
Start date1 July 2020
Primary completion1 September 2022
Estimated completion30 March 2025
Sites5 locations across Greece

Drugs / interventions tested

Conditions studied

Sponsor

University of Athens

Who can join

18 and older, any sex, with Transcatheter Aortic Valve Replacement. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Single arm, observational trial of Transcatheter Aortic Valve Implantation (TAVI) with the Medtronic Evolut R and Evolut Pro The primary objective of this trial is to evaluate device success of TAVI with the Evolut R and Evolut Pro systems in septuagenarians with risk factors for adverse surgical outcomes not captured by the traditional risk scores and therefore of intermediate surgical risk.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Transcatheter Aortic Valve Implantation (TAVI)

Trials testing the same drug.

Other recruiting trials for Transcatheter Aortic Valve Replacement

Currently open trials in the same condition.

Other University of Athens trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04517955.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing